Reply: De novo SPTAN1 mutation in axonal sensorimotor neuropathy and developmental disorder

Longitudinal neurodevelopmental profile of a pediatric patient with de novo SPTAN1, epilepsy, and left hippocampal sclerosis

•

We present the first longitudinal study of neuropsychological functioning in a pediatric patient with SPTAN1.

•

To our knowledge we report the first case of SPTAN1 heterozygosity in a patient with MTLE due to HS.

•

This case is the first to show that lisdexamfetamine dimesylate improved attention, behavior, and school performance in a patient with heterozygous SPTAN1 variant.

Pathogenic variants in SPTAN1 result in abnormal neurodevelopment but limited information is available on the spectrum of neurodevelopmental profiles associated with variations in this gene. We present novel data collected at two time points over a three-year period in a nine-year-old patient with heterozygous de novo SPTAN1 variant, drug-resistant epilepsy, and left hippocampal sclerosis. Across evaluations, our patient’s performance was highly variable, ranging from below age expectation to within age-expected range. The patient exhibited relative cognitive strengths at both time points on verbal-expressive tasks. Weaknesses were seen in her attention, executive function, psychomotor processing speed, fine motor, visual-motor integration, and social skills. Memory findings were consistent those associated with left hippocampal sclerosis. Evaluations resulted in diagnoses including attention deficit hyperactivity disorder and autism spectrum disorder.